Business Description
Erasca Inc
NAICS : 541714
SIC : 2834
ISIN : US29479A1088
Description
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 5.5 | |||||
| Equity-to-Asset | 0.82 | |||||
| Debt-to-Equity | 0.16 | |||||
| Debt-to-EBITDA | -0.4 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -83.6 | |||||
| 3-Year EPS without NRI Growth Rate | -124.4 | |||||
| 3-Year FCF Growth Rate | -83.1 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 15.56 | |||||
| 9-Day RSI | 23.67 | |||||
| 14-Day RSI | 30.71 | |||||
| 6-1 Month Momentum % | -12.37 | |||||
| 12-1 Month Momentum % | -65.63 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 13.9 | |||||
| Quick Ratio | 13.9 | |||||
| Cash Ratio | 13.62 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -29.6 | |||||
| Shareholder Yield % | -7.78 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -61.34 | |||||
| ROA % | -50.93 | |||||
| ROIC % | -163.82 | |||||
| ROC (Joel Greenblatt) % | -248.7 | |||||
| ROCE % | -34.16 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.93 | |||||
| Price-to-Tangible-Book | 0.93 | |||||
| EV-to-EBIT | -0.54 | |||||
| EV-to-EBITDA | -0.56 | |||||
| EV-to-FCF | -0.63 | |||||
| Price-to-Net-Current-Asset-Value | 1.37 | |||||
| Price-to-Net-Cash | 1.42 | |||||
| Earnings Yield (Greenblatt) % | -185.19 |
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ERAS
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Erasca Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.78 | ||
| Beta | 0 | ||
| Volatility % | 42.58 | ||
| 14-Day RSI | 30.71 | ||
| 14-Day ATR ($) | 0.134287 | ||
| 20-Day SMA ($) | 2.53975 | ||
| 12-1 Month Momentum % | -65.63 | ||
| 52-Week Range ($) | 2.24 - 9.25 | ||
| Shares Outstanding (Mil) | 151.04 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Erasca Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Erasca Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Erasca Inc Frequently Asked Questions
What is Erasca Inc(ERAS)'s stock price today?
The current price of ERAS is $2.25. The 52 week high of ERAS is $9.25 and 52 week low is $2.24.
When is next earnings date of Erasca Inc(ERAS)?
The next earnings date of Erasca Inc(ERAS) is 2023-11-09 Est..
Does Erasca Inc(ERAS) pay dividends? If so, how much?
Erasca Inc(ERAS) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers